Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Clinical trial NCT06259721 · UNKNOWN
Trial details
- NCT number
- NCT06259721
- Sponsor
- Jiangxi Provincial Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-10
- Primary completion
- 2026-02-09
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.